Related Experiment Videos

Significant gastrointestinal bleeding in patients at risk of coronary stent thrombosis

Xuming Dai1, Amgad N Makaryus, John N Makaryus

  • 1Division of Cardiology, North Shore-Long Island Jewish Health System, New Hyde Park, New York, USA.

Reviews in Cardiovascular Medicine
|April 16, 2009
PubMed

Insights

Long-term antiplatelet therapy after drug-eluting stents (DES) prevents stent thrombosis but increases bleeding risk. Proton pump inhibitors or H. pylori eradication may benefit patients on DES therapy.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Gastroenterology

Background:

  • Percutaneous coronary interventions, including drug-eluting stents (DES), have increased, necessitating effective antithrombotic strategies.
  • Stent thrombosis remains a critical complication following coronary stent implantation, requiring long-term antiplatelet therapy.
  • Discontinuation of antiplatelet therapy is a primary risk factor for stent thrombosis.

Observation:

  • Long-term antiplatelet therapy, while crucial for preventing stent thrombosis, is associated with significant bleeding complications, predominantly in the upper gastrointestinal (GI) tract.
  • Aspirin use is linked to an elevated risk of upper GI bleeding, with peptic ulcer bleeding and Helicobacter pylori infection being key contributing factors.
  • Endoscopy is the main diagnostic and interventional tool for managing GI bleeding.

Findings:

  • The risk of GI bleeding increases with prolonged antiplatelet therapy duration.
  • H. pylori infection and peptic ulcer disease are significant risk factors for GI bleeding in patients on aspirin therapy.
  • The benefits of long-term antiplatelet therapy must be weighed against the risks of bleeding complications.

Implications:

  • Adjunctive proton pump inhibitor (PPI) therapy may mitigate GI bleeding risk in patients on long-term antiplatelet therapy post-DES.
  • Eradication of H. pylori infection could be a beneficial strategy for reducing GI bleeding complications in this patient population.
  • Further research is warranted to optimize antithrombotic and gastroprotective strategies for patients undergoing percutaneous coronary interventions.

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...